ABBV
GMAB
Big win, bigger questions
Genmab just dropped topline Phase 3 data from EPCORE DLBCL-4, and the headline is the kind biotech investors love: the study hit its primary endpoint. In plain English, the epcoritamab + lenalidomide combo outperformed the standard-of-care R-GemOx regimen in adults with relapsed or refractory diffuse large B-cell lymphoma.
Why the market is perking up
This wasn’t a tiny statistical shrug. The company said progression-free survival improved meaningfully, with the risk of progression and death cut by 60% under one censoring rule and 56% under another. That’s the sort of result that makes analysts start daydreaming about label expansion instead of just incremental sales.
The not-so-hidden prize
William Blair is basically peeking over the fence and seeing a much larger backyard. The firm says the data support a possible second-line-plus DLBCL label expansion, a population Genmab pegs at about 21,000 patients. And if that weren’t enough, the readout also adds some sparkle to the upcoming EPCORE DLBCL-2 trial in frontline DLBCL, which is slated for 2026 and could open the door to a much bigger pool of roughly 70,000 patients.
Big picture
For biotech, good data is the oxygen tank. If epcoritamab keeps stacking up wins, Genmab and AbbVie could turn this from a promising antibody into a real franchise — the kind that makes a $16 billion market cap look a little less sleepy.